GTx Ipsen team ends

Memphis-based GTx, backed by Pitt Hyde and others, yesterday announced the end of its toremifine collaboration with Ipsen, which had stepped into the partnership slot after Merck left. The MDN reports.

GTx distress frees cancer drug

An adverse FDA ruling against GTx may actually have helped spur the Memphis company to take a useful anti-breast cancer drug, Fareston, off the shelf and market it more aggressively as an alternative to Tamoxifen. The CA reports.

Biopharma: GTx, Provectus report progress

Memphis-based GTx and Knoxville-based Provectus reported gains toward development of key products.

Pitt Hyde invests more in GTx in Memphis

GTx, the Memphis biopharma development company, not only raised $37.6m in a stock offering yesterday, but got more help from AutoZone founder-entrepreneur-investor Pitt Hyde (at left), who invested $15.3m in the company, reports MDN. MBJ reports on GTX's 3Q results.

GTx in $40MM stock offering

GTx, the Memphis pharma company, has filed for a $40MM gross proceeds offering, the MBJ has it.

GTx marches on

Memphis-based GTx Inc. marches onward, hoping yet to convince the FDA to approve Acapodene for use in fighting bone fractures in men taking chemo for prostate cancer. MDN reports. It wasn't so long ago, we note, that Nashville-based BioMimetic had to shrug-off an FDA bruise, and continues to move along.

GTx target after FDA blow

Memphis-based GTx may be an acquisition target, in the wake of an FDA adverse ruling on a clinical trial that sent its stock reeling. The CA reports. A fuller story also appears in today's Memphis Daily News. The situation vividly illustrates the type risks many Tennessee VCs say they can live without. MB Venture Partners exited the stock at its IPO in 2006.

Make it Stop: Sci-tech news here and there

UT Pres. John Petersen says companies are lining-up to take residence in new Cherokee Farms sci-tech park and credits ORNL alliance with elevating UT's stature, KNS.

Don't let anyone tell you there's no interest in LifeSci here in NV: strong response to our story yesterday on KleinerPerkins-based Nodality establishing lab here. Story with Stanford ties does leave one wondering about similar cytometry work that might be underway at VU.

Speakin' of which, Frank Munger says Stanford Ph.D. George Farr will head the new UT-ORNL materials institute.

Great story in the CA this morn about Memphis entrepreneur Dick Gadomski founder of 35-year-old Process Solutions Inc. (PSI).

Resonant Vibes (Louisville) recruited nearly $900K to support RV's downloads service, drawing on KY Science & Technology Corp.'s KY Enterprise Fund, the Commonwealth Seed Capital Fund and private investors in Louisville, Lexington and NYC.

Health IT shouldn't be used to automate bad business processes, but to improve healthcare outcomes. Getahn Ward quotes VUMC's Bill Stead, co-author of widely noted National Research Council study.

Sorry, but this is just gettin' weird: WSJ's Mossberg today on using Google's new feature to track Friends.

Medtronic engineers are giving the time and the company's given the cash to help Memphis public-schools' teams build a robot for the FIRST competition. CA.

MDN reports GTx Inc. got a vote of confidence Jan. 22 when Medtronic board member and former Abbott Labs CEO Jack Schuler bought 8.3 percent of GTx stock. A pharma analyst gave the company high marks, partly because of its drug-apps pipeline, as projected to 2011.

AT&T Kentucky announced that Mary Pat Regan, who previously headed-up regulatory affairs in Illinois, has been named president of AT&T Kentucky.

TVA urged to convert flyash-spill area into long-term research and education center to study enviro-impact, KNS. Gov. Bredesen has asked TVA to find ways to recycle coal ash.

GTx inserts another drug into FDA

Memphis-based and NASDAQ-listed GTx, Inc., this week announced its submission of a New Drug Application to the FDA, covering an oral selective estrogen receptor modulator (SERM) for prevention of bone fractures in men with prostate cancer and undergoing androgen-hormone deprivation therapy. The GTx release is here. [Update: Jan. 5 - Memphis Daily News reported that a lawsuit involving GTx, the UT Foundation and Merck has been settled. GTx's SEC filing is here.)